Semaglutide vs Dulaglutide for HbA1c, Body Weight Reduction in T2D

Share this content:
A GLP-1 analog, semaglutide, demonstrated meaningful HbA1c and body weight reductions across the SUSTAIN clinical trial program.
A GLP-1 analog, semaglutide, demonstrated meaningful HbA1c and body weight reductions across the SUSTAIN clinical trial program.
The following article is part of conference coverage from the American Diabetes Association's 78th Scientific Sessions (ADA 2018) in Orlando,Florida. Endocrinology Advisor's staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back for the latest news from ADA 2018.

ORLANDO — Semaglutide used to treat individuals with type 2 diabetes showed a greater reduction in blood glucose levels and body weight compared with those treated with dulaglutide, regardless of baseline measurements of glycated hemoglobin (HbA1c). This research was presented at the American Diabetes Association's 78th Scientific Sessions held in Orlando, Florida, June 22 - 26, 2018.

This post-hoc study examined individuals with type 2 diabetes according to treatment with either once-weekly subcutaneous semaglutide 0.5 mg vs dulaglutide 0.75 mg and semaglutide 1 mg vs dulaglutide 1.5 mg; subgroups were further analyzed by baseline HbA1c.

Study results showed that, at week 40, treatment effects were similar or favored semaglutide, and reductions in HbA1c and body weight were similar across all subgroups. The study further saw a higher proportion of patients with a baseline HbA1c of > 9% achieved blood glucose targets using semaglutide compared with patients treated with dulaglutide.

Investigators conclude that semaglutide was associated with similar or greater outcomes for managing type 2 diabetes compared with dulaglutide; semaglutide showed to improve blood glucose levels and reduce body weight in all patients despite differences in baseline HbA1c measurements.

This study was supported by Novo Nordisk Inc. Please refer to reference for a complete list of authors' disclosures.

For more coverage of ADA 2018, click here. 

Reference

Pratley RE, Frias JP, Kumar H, et al. Efficacy of semaglutide vs. dulaglutide across baseline HbA1c in SUSTAIN 7. Paper presentation at: ADA 2018 78th Scientific Sessions; June 22-26, 2018; Orlando, FL. Abstract 122-OR.

You must be a registered member of Endocrinology Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-Newsletters